Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
07:00pm, Thursday, 03'rd Feb 2022
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
02:00am, Tuesday, 04'th Jan 2022
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Canaccord Genuity Boosts Verona Pharma (NASDAQ:VRNA) Price Target to $23.00
10:54am, Monday, 15'th Nov 2021 Transcript Daily
Verona Pharma (NASDAQ:VRNA) had its price objective hoisted by Canaccord Genuity from $18.00 to $23.00 in a report released on Friday morning, Price Targets.com reports. Canaccord Genuity currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on VRNA. Zacks Investment Research cut shares of Verona Pharma []
Verona Pharma (NASDAQ:VRNA) Price Target Increased to $23.00 by Analysts at Canaccord Genuity
10:20am, Monday, 15'th Nov 2021 Dakota Financial News
Verona Pharma (NASDAQ:VRNA) had its price target hoisted by Canaccord Genuity from $18.00 to $23.00 in a research report released on Friday, Analyst Price Targets reports. Canaccord Genuity currently has a buy rating on the stock. Other equities analysts also recently issued reports about the stock. HC Wainwright began coverage on shares of Verona Pharma []
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
02:32pm, Tuesday, 09'th Nov 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
Verona Pharma Announces November 2021 Investor Conference Participation
03:00am, Monday, 01'st Nov 2021
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Tuesday, 26'th Oct 2021
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
02:00am, Wednesday, 13'th Oct 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
02:00am, Thursday, 02'nd Sep 2021
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmac
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
02:00am, Tuesday, 31'st Aug 2021
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
10:28am, Saturday, 07'th Aug 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
02:00am, Thursday, 05'th Aug 2021
ENHANCE Phase 3 program on track to report top-line data in 2022
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
02:00am, Tuesday, 27'th Jul 2021
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Thursday, 22'nd Jul 2021
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
04:20pm, Sunday, 13'th Jun 2021
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
